Parkinson's drug study aims to uncover disease clues

NCT ID NCT05677633

Completed Knowledge-focused Sponsor: University of Nebraska Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested the safety of a drug called sargramostim (Leukine) in 11 people with Parkinson's disease over 48 weeks. Researchers also looked for changes in immune cells and other biomarkers that might help track the disease. The goal was not to cure Parkinson's but to better understand how the body responds to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sargramostim (Leukine)
What this could lead to: If successful, this study could help identify biomarkers that track Parkinson's disease progression and response to treatment, potentially guiding future therapies.
What could go wrong: This is a very small, early-phase trial with only 11 participants, focused on safety and biomarker validation rather than proving effectiveness. Results may not apply to all Parkinson's patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE AND PARKINSONISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease parkinsonian disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON'S DISEASE AND PARKINSONISM

Contacts and locations

Locations

University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.